Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
GlaxoSmithKline
Scientific Title
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma